Table of Contents
- What Is Treatment-Resistant Depression?
- How Spravato Therapy for Treatment-Resistant Depression Works
- Spravato Side Effects and Safety: What Patients Should Know
- How Long Does Spravato Treatment Last?
- Who Is a Candidate for Spravato Therapy?
- Insurance Coverage for Spravato: Navigating the Costs
- Your Day-of-Treatment Experience and Psychological Support
- Conclusion
Last Updated: August 28, 2026
What Is Treatment-Resistant Depression?
Treatment-resistant depression is major depressive disorder in which a patient has not experienced adequate symptom relief after trying at least two different antidepressant medications at adequate doses and durations. This definition determines eligibility for advanced interventions, including Spravato therapy.
Many patients cycle through multiple medications over years, experiencing partial relief at best. The emotional weight of that cycle, hope, waiting, disappointment, is something clinicians at Salado Creek Mental Health hear about regularly from patients who arrive exhausted and skeptical.
What distinguishes treatment-resistant depression is the documented failure of standard pharmacotherapy, which changes the risk-benefit calculation for treatments like esketamine nasal spray. According to the National Institute of Mental Health overview of depression treatments, a meaningful subset of patients do not respond adequately to first-line treatments. For those patients, FDA-approved options like Spravato represent a genuine shift in what is clinically possible.
Treatment-resistant depression is defined by the failure of at least two adequate antidepressant trials, not simply by symptom severity. That clinical definition determines eligibility for Spravato and other advanced treatments.
How Spravato Therapy for Treatment-Resistant Depression Works
Spravato therapy works through a fundamentally different mechanism than traditional antidepressants. Most oral antidepressants target the serotonin or norepinephrine systems. Spravato’s active ingredient, esketamine, targets the glutamate system, specifically acting on NMDA receptors to promote neuroplasticity and restore synaptic connections that depression has disrupted.
This glutamate receptor modulation produces rapid symptom relief in ways oral antidepressants cannot. Standard antidepressants often require four to eight weeks before meaningful change. Spravato’s effects on mood can begin within hours to days of the first administration for some patients. That speed matters enormously for someone who has been waiting years for relief.
FDA Approval and Clinical Indications
The FDA approved esketamine nasal spray, marketed as Spravato, in 2019 for adults with treatment-resistant depression and for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior. Both indications require Spravato as adjunctive therapy alongside an oral antidepressant, not as standalone monotherapy.
The FDA’s approval was based on clinical trial data demonstrating statistically significant reductions in depression symptom scores compared to placebo. According to FDA prescribing information and approval documentation for Spravato, the drug is only available through the Spravato REMS (Risk Evaluation and Mitigation Strategy), which requires administration in a certified healthcare setting with mandatory post-dose monitoring.
This is not a medication patients take at home. That distinction shapes everything about how treatment is structured.
The In-Office Administration Process
Every Spravato session follows a structured protocol. The patient self-administers the nasal spray under direct clinical supervision. After administration, the patient remains in the clinical setting for at least two hours of monitoring for dissociative symptoms, sedation, blood pressure changes, nausea, and dizziness.
Dissociation is a known pharmacological effect of ketamine-class compounds. For most patients it is mild and transient, resolving before the monitoring period ends. Blood pressure monitoring occurs at multiple points because esketamine can cause transient elevations.
Patients cannot drive themselves home after a session. Arranging transportation is a logistical requirement.
Spravato Side Effects and Safety: What Patients Should Know
The Spravato side effects and safety profile is well-characterized from clinical trials and post-marketing studies. Understanding it honestly is essential for informed patient selection.
The most commonly reported adverse events include:
- Dissociation: A sense of detachment from surroundings or altered perception of time. Usually mild to moderate and resolves within the two-hour monitoring period.
- Dizziness: Particularly in the first hour post-administration. Patients remain seated.
- Nausea: Reported by a meaningful portion of patients, particularly in early sessions. Often decreases over the induction phase.
- Sedation: Drowsiness during and immediately after the session is common.
- Blood pressure elevation: Transient increases are monitored at defined intervals. Patients with poorly controlled hypertension require careful evaluation.
The REMS program exists because dissociation and sedation require trained supervision. Certified treatment centers must follow strict protocols for monitoring and documentation.
A neurological assessment and psychiatric evaluation are standard components of pre-treatment workup. Contraindications include a history of certain vascular conditions, aneurysmal vascular disease, and active psychosis. Thorough patient selection ensures the right patients receive the treatment.
Never attempt to obtain or use esketamine outside a certified clinical setting. The REMS program exists because the dissociative and cardiovascular effects of esketamine require trained supervision. Home use is not approved and carries serious safety risks.
How Long Does Spravato Treatment Last?
Spravato treatment is a structured course divided into two phases.
| Phase | Frequency | Typical Duration |
|---|---|---|
| Induction | Twice weekly | 4 weeks (8 sessions) |
| Maintenance (initial) | Once weekly | 4 weeks |
| Maintenance (ongoing) | Every 1-2 weeks | Ongoing, individualized |
Induction Phase
The induction phase is the most intensive part of Spravato therapy. Patients typically receive two sessions per week for four weeks, totaling eight sessions. The goal is to establish a therapeutic response and determine whether the patient is achieving meaningful symptom reduction and tolerating the treatment well.
Some patients notice improvement early in induction. Others require the full course before a clear picture emerges. Clinical teams monitor symptom scores throughout using validated rating scales.
The twice-weekly schedule is demanding. Patients need to factor in travel, the two-hour post-dose monitoring period, and the remainder of the day when driving is not permitted. Planning this schedule in advance reduces friction significantly.
Maintenance Phase and Long-Term Strategies
After induction, patients who have achieved a therapeutic response move into the maintenance phase. Frequency drops to once weekly for four weeks, then to every one to two weeks on an individualized schedule. Long-term relapse prevention becomes central.
Current clinical practice supports continuing maintenance treatment in patients who have responded well. Discontinuing too early carries a real risk of relapse, particularly for patients with a history of multiple depressive episodes.
Long-term maintenance strategies typically combine ongoing Spravato sessions with continued oral antidepressant therapy and psychotherapy. The combination addresses both neurobiological and psychological dimensions of treatment-resistant depression. According to American Psychiatric Association practice guidelines for major depressive disorder, combining pharmacotherapy with psychotherapy generally produces better long-term outcomes than medication alone.
Patients who build a consistent support structure during maintenance, including therapy, sleep hygiene, and social connection, tend to sustain gains more durably. Spravato opens a neurobiological window; what patients do with that window matters.
Who Is a Candidate for Spravato Therapy?
Patient selection criteria for Spravato are specific. The treatment is approved for adults with treatment-resistant depression as defined by the FDA indication. Candidates must have documented failure of at least two adequate antidepressant trials.
A thorough psychiatric evaluation assesses:
- Diagnosis confirmation (major depressive disorder, not bipolar depression or another primary condition)
- Medication history, including doses and durations of prior trials
- Cardiovascular history, particularly conditions affecting blood pressure or vascular integrity
- History of psychosis or dissociative disorders, which are contraindications
- Substance use history
- Current medications for drug interaction review
Patients who are pregnant, breastfeeding, or who have certain cardiovascular conditions are not candidates. The pre-treatment workup protects patients from harm.
For patients who meet criteria, the clinical benefit can be substantial. Spravato is one of the few FDA-approved pharmacological advances specifically designed for treatment-resistant depression.
Patients typically continue their current antidepressant when starting Spravato. Spravato is approved as adjunctive therapy and is added to an existing oral antidepressant regimen, not substituted for one.
Insurance Coverage for Spravato: Navigating the Costs
Insurance coverage for Spravato is available through many major plans, but prior authorization is required. Most insurers require evidence of treatment-resistant depression, records showing that at least two antidepressants have been tried and failed. That documentation aligns with the FDA indication, so patients who meet clinical criteria generally have a credible prior authorization pathway.
Medicare and Medicaid both cover Spravato for eligible patients, though coverage specifics vary by plan and state. Commercial insurance coverage varies widely.
The cost of Spravato without insurance is substantial. The manufacturer operates a patient assistance program for eligible patients, and copay assistance programs may apply for commercially insured patients who meet income criteria.
For patients concerned about out-of-pocket costs, benefits verification before starting treatment is the most productive first step. A clinical team can help navigate prior authorization and identify available financial assistance. Salado Creek Mental Health offers a complimentary brief phone consultation to understand both clinical eligibility and coverage logistics.
Your Day-of-Treatment Experience and Psychological Support
Most patients arrive at their first Spravato session uncertain about what to expect. Knowing what the day looks like reduces anxiety.
A typical treatment day follows this sequence:
- Arrival and check-in: Vital signs, including blood pressure, are taken before administration.
- Pre-dose preparation: The patient settles into a comfortable, private treatment space. Many bring headphones and a playlist.
- Self-administration: The patient administers the nasal spray under clinical supervision.
- Monitoring period: The two-hour observation window begins. Staff check in at defined intervals. Dissociative effects, if present, typically peak within the first hour and resolve before the monitoring period ends.
- Post-session assessment: Vital signs are rechecked before discharge.
- Transportation home: The patient leaves with their pre-arranged driver.
Psychological support during administration is an underappreciated part of effective Spravato therapy. The dissociative state some patients experience can surface unexpected thoughts or emotions. Having a supportive clinical presence and a concurrent relationship with a therapist gives patients a framework for processing what arises.
For patients with demanding or irregular schedules, the logistics of twice-weekly sessions during induction can feel like a barrier. Salado Creek Mental Health offers after-hours Spravato services to make the treatment accessible to patients whose lives don’t fit a standard schedule.
Many patients describe a shift in their internal experience during maintenance, greater capacity to engage with therapy, reduced hopelessness, returning interest in things that had gone flat. That shift is the neuroplasticity effect in practice. The clinical team’s role is to support patients in using it.
Treatment-resistant depression is one of the most difficult challenges in psychiatric care. Finding a provider who treats the whole person, not just the diagnosis, makes a real difference in outcomes. Salado Creek Mental Health provides patient-centered Spravato therapy with after-hours availability, individualized treatment planning, and a team committed to making patients feel heard. To find out whether Spravato therapy is the right next step for you, schedule a complimentary phone consultation with the Salado Creek Mental Health team today.
Frequently Asked Questions
What disqualifies a patient from receiving Spravato therapy?
Several conditions can make Spravato unsuitable. These include a history of aneurysmal vascular disease, arteriovenous malformation, a history of intracerebral hemorrhage, and certain cardiovascular conditions where blood pressure spikes pose serious risk. Patients with active psychosis or a history of hypersensitivity to esketamine or ketamine are also excluded. Pregnancy disqualifies patients as well. A thorough psychiatric evaluation will identify any contraindications before treatment begins.
How does Spravato differ from traditional oral antidepressants?
Traditional oral antidepressants primarily target serotonin, norepinephrine, or dopamine systems and can take four to eight weeks to produce noticeable results. Spravato works through glutamate receptor modulation, a different neurological pathway, and is associated with more rapid symptom relief, sometimes within hours or days. It is also administered in a certified clinical setting under direct supervision rather than taken at home, and it is used as an adjunctive therapy alongside an oral antidepressant, not as monotherapy.
Is Spravato covered by insurance for treatment-resistant depression?
Many major insurance plans, including Medicare and Medicaid, cover Spravato for FDA-approved indications such as treatment-resistant depression and major depressive disorder with acute suicidal ideation. Coverage typically requires prior authorization and documentation that at least two oral antidepressants failed. Out-of-pocket costs vary widely based on your plan's deductible, copay structure, and whether the provider is in-network. Contact your insurer directly and ask the clinic about any available financial assistance programs.
How long do patients typically remain on Spravato treatment?
Treatment duration varies by individual response. The induction phase generally runs four weeks, with two sessions per week. Patients who respond then move to a maintenance phase, which typically involves weekly sessions for a month, followed by sessions every one to two weeks on an ongoing basis. Some patients continue maintenance treatment for a year or longer to support relapse prevention. Your prescribing provider will reassess your therapeutic response regularly and adjust the schedule based on your clinical progress.
